-+ 0.00%
-+ 0.00%
-+ 0.00%

Neurocrine Biosciences Presents New Phase 4 Analysis Showing INGREZZA Improves Function & Quality Of Life In Tardive Dyskinesia Patients

Benzinga·05/16/2025 12:30:59
Listen to the news
  • Patients Treated with INGREZZA® (valbenazine) Capsules Reported Continued Improvements in Functional and Health-Related Quality of Life Measures
  • Findings Presented at 2025 International Society for Pharmacoeconomics and Outcomes Research Conference

SAN DIEGO, May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the presentation of new analyses from a Phase 4 randomized withdrawal study (NCT03891862) showing patients with tardive dyskinesia who received continued treatment with INGREZZA® (valbenazine) capsules reported improvements across functional and health-related quality of life measures. These findings complement recently announced patient-reported outcome data from the Phase 4 KINECT-PRO™ study of INGREZZA, which was the first of its kind to specifically measure and report clinically meaningful improvements in the impact of tardive dyskinesia. The analyses were presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference in Montreal, Canada.